Ryan has been covering the medical device and consumer health, wellness and beauty sectors since 2004, first as a reporter for Gray Sheet, where he covered beats including Capitol Hill, international and emerging technology, and then as managing editor of Rose Sheet. In his current role, he oversees and heads up strategy for their successor publications Medtech Insight and HBW Insight. He also manages and contributes regularly to HBW Insight’s Beauty channel with a focus on regulatory, policy and legal issues and has moderated related panels at industry events. Ryan has a growing role in developing podcasts, new features, “deep dive” article series, and infographics across teams and publications. Off the job, he enjoys spending time with his wife Katie, son Finn and daughter Maggie in Alexandria, VA, a DC suburb.
Latest from Ryan Nelson
In this week’s Digital Health Roundup, Medtech Insight’s Ryan Nelson highlights Click Therapeutics’ FDA-cleared digital therapeutics (DTx) for depression and Sinaptica Therapeutics’ personalized neuromodulation for Alzheimer’s patients. Marion Webb discusses her interview with MindMaze’s John Krakauer on their gaming-focused DTx to help people recover from serious brain injuries. Elizabeth Orr introduces new voting members of the new Digital Health Advisory Committee and Natasha Barrow discusses Hello Heart’s new symptom-tracking feature in their heart-focused app.
MamaLift Plus, 510(k)-cleared by the FDA in April as the first prescription digital therapeutic for treating postpartum depression, will soon be available for download on the App Store or Google Play. Announced 28 August, Curio has raised $10m in Series A funding to bolster commercial activities.
Following FDA clearance of its Edison Histotripsy System in October 2023 for the non-invasive destruction of liver tumors using focused ultrasound, HistoSonics announces plans for $102m in new funding led by Alpha Wave Ventures. “Bubbles have never been so powerful,” the company says.
The Seattle-WA-based company’s latest capital raise follows study results published in July in which Know Labs’ proprietary non-invasive RF dielectric sensor and machine learning algorithms correctly classified participants’ glycemic status as hyperglycemic, normoglycemic, or hypoglycemic with 93.37% accuracy compared with venous blood glucose values. Know Labs' goal is to commercialize a diabetes screening device that could help to funnel undiagnosed patients into the health care system.
The Seattle-WA-based company’s latest capital raise follows study results published in July in which Know Labs’ proprietary non-invasive RF dielectric sensor and machine learning algorithms correctly classified participants’ glycemic status as hyperglycemic, normoglycemic, or hypoglycemic with 93.37% accuracy compared with venous blood glucose values. Know Labs' goal is to commercialize a diabetes screening device that could help to funnel undiagnosed patients into the health care system.
The MI/MCI preservative combination is a suspect being explored by FDA as part of its investigation into reports of hair loss and other adverse effects linked to WEN Cleansing Conditioners. The agency discusses testing it undertook to quantitate the WEN products’ MI/MCI content in a response to concerns raised by Democratic Congressman Frank Pallone of New Jersey.